Cart
sales@molnova.com
LMPTP INHIBITOR 1 dihydrochloride
CAS No. 2310135-46-5
LMPTP INHIBITOR 1 dihydrochloride( —— )
Catalog No. M28358 CAS No. 2310135-46-5
LMPTP INHIBITOR 1 dihydrochloride is a selective inhibitor of low molecular weight protein tyrosine phosphatase (LMPTP), with an?IC50?of 0.8 μM LMPTP-A.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 155 | Get Quote |
|
| 10MG | 250 | Get Quote |
|
| 25MG | 465 | Get Quote |
|
| 50MG | 673 | Get Quote |
|
| 100MG | 945 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLMPTP INHIBITOR 1 dihydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionLMPTP INHIBITOR 1 dihydrochloride is a selective inhibitor of low molecular weight protein tyrosine phosphatase (LMPTP), with an?IC50?of 0.8 μM LMPTP-A.
-
DescriptionLMPTP INHIBITOR 1 dihydrochloride is a selective inhibitor of low molecular weight protein tyrosine phosphatase (LMPTP), with an?IC50?of 0.8 μM LMPTP-A.(In Vitro):LMPTP INHIBITOR 1 dihydrochloride is a selective inhibitor of low molecular weight protein tyrosine phosphatase, with an IC50?of 0.8 μM LMPTP-A and shows more potent effect on LMPTP-A versus LMPTP-B. LMPTP inhibitor 1 dihydrochloride (10 μM) also enhances HepG2 IR phosphorylation after insulin stimulation in human HepG2 hepatocytes.(In Vivo):LMPTP inhibitor 1 dihydrochloride is orally bioavailable, and results in appr 680 nM mean serum concentration after treatment of 0.03% w/w, while treatment with 0.05% w/w results in >3 μM; also reverses diabetes in obese mice. LMPTP inhibitor 1 dihydrochloride (0.05% w/w) inhibits LMPTP activity, significantly improves glucose tolerance and decreases fasting insulin levels of diabetic DIO mice, without affecting body weight.
-
In VitroLMPTP INHIBITOR 1 (dihydrochloride) is a selective inhibitor of low molecular weight protein tyrosine phosphatase, with an IC50 of 0.8 μM LMPTP-A and shows more potent effect on LMPTP-A versus LMPTP-B. LMPTP inhibitor 1 (Compound 23; 10 μM) also enhances HepG2 IR phosphorylation after insulin stimulation in human HepG2 hepatocytes.
-
In VivoLMPTP inhibitor 1 is orally bioavailable, and results in appr 680 nM mean serum concentration after treatment of 0.03% w/w, while treatment with 0.05% w/w results in >3 μM; also reverses diabetes in obese mice. LMPTP inhibitor 1 (0.05% w/w) inhibits LMPTP activity, significantly improves glucose tolerance and decreases fasting insulin levels of diabetic DIO mice, without affecting body weight.
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetPhosphatase
-
RecptorE3 Ligase Ligand-Linker Conjugate
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2310135-46-5
-
Formula Weight517.54
-
Molecular FormulaC28H38Cl2N4O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 64 mg/mL (123.66 mM)
-
SMILESCl.Cl.CCN(CC)C(=O)c1ccc(cc1)-c1cc(NCCCN2CCCCC2)c2ccccc2n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Qiu X, et al. Jiang B. Chemoselective Synthesis of Lenalidomide-Based PROTAC Library Using Alkylation Reaction. Org Lett. 2019;21(10):3838-3841.
molnova catalog
related products
-
DA-3003-1
DA-3003-1 (DA-3003-1) is a membrane-permeable, potent and selective Cdc25 dual specificity phosphatase inhibitor with antitumor activity that inhibits Cdc25B2, Cdc25A, Cdc25B2 and Cdc25C.
-
MY10
MY10, a potent and orally active inhibitor of the receptor protein tyrosine phosphatase (RPTPβ/ζ), effectively reduces binge-like ethanol consumption and diminishes the rewarding effects of ethanol.
-
[pTyr5] EGFR 988-993
[pTyr5] EGFR (988-993) is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B).
